Innovent Biologics, a Chinese biomedical developer backed by Singapore’s Temasek Holdings, filed for an initial public offering (IPO) in Hong Kong after the bourse opened the door for pre-profit biotech startups to list. Innovent didn’t disclose the …
( read original story …)